All News

mind-the-gap-1876790_640.jpg

#WomenInRheumatology: Is There a Speaker Gender Gap at ACR Meetings?

d Kanika Monga, MD

Recent studies have quantified the gender gap among speakers at academic conferences. The largest study of 181 medical conferences held in North America over one decade found an increase in the proportion of female speakers from 25 to 34% over time, and that the underrepresentation of women was more marked at surgical compared to medical conferences.

Read Article
xray%20spine%20films_0.jpg

IL-17 Inhibitors In Non-Radiographic Axial SpA

d Philip Robinson, MBChB, PhD, FRACP

This meeting sees new data on using anti-IL-17 agents in non-radiographic axial SpA. Up until now these patients have only had TNF inhibitors available, so data about the efficacy of IL17 inhibitors is really important.

Read Article
(the Fonz says) Tenacity and gratitude are 2 words to live by. - Henry Winkler

Dr. John Cush RheumNow ( View Tweet)

Me and ⁦@AdamJBrownMD⁩ of Rheumination game in the studio to do ⁦@VindicoMedEd⁩ curbside consults on GCA! Sometimes the Dx is NOT so easy!!!Stay tuned to us and ⁦@HealioRheum⁩ ⁦@AWIRGROUP⁩ ⁦@RheumNow⁩ ⁦@VasculitisFound⁩ ⁦@ramos_casals⁩ https://t.co/nnMC9r5LsH

Leonard Calabrese LCalabreseDO ( View Tweet)

Looks like the latest ACR on Air podcast is up — episode 5 — recorded during #ACR19 with host @hausmannMD and @DrBhana and myself as guests. We discuss a couple of our favorite abstracts from the meeting. @ACRheum https://t.co/WHNiHuhenZ

Dr. Paul Sufka psufka ( View Tweet)
Very cool minilecture on how to read RCTs! https://t.co/jQUawxcEr1

Links:

Dr. John Cush RheumNow ( View Tweet)

Gout Attacks Intensify with Heart Failure #cardiovascular https://t.co/LxCw8sCv5P https://t.co/ZukMrWuaeF

Links:

Rheumatology Network RheumatologyNet ( View Tweet)
Our new review article is online detailing airway inflammation and RA pathogens is - Obstructive lung diseases and risk of rheumatoid arthritis https://t.co/Nmj9Uf6isl https://t.co/ByWVI0fYwa

Links:

Jeff Sparks jeffsparks ( View Tweet)
Guselkumab, anti-IL23 in PsA Ph3 DISCOVER-1 trial in bio-naive or 30% prior TNFi = Effective at Wk 24 Safety same as with psoriasis trials. No Tb signal, No IBD signal. #ACR19 Abst0807 @_connectedcare https://t.co/d7hrn8VQO8

Links:

Dr. John Cush RheumNow ( View Tweet)

Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/45Vahy36g7 #ACR19 @uptoTate abs#2881

Links:

Dr. John Cush RheumNow ( View Tweet)

I didn’t realize how fast Pegloticase works. Assuming the urate burden of a gout patient, Pegloticase can degrade all the urate in the body over 5-40 days! #ACR19 3S050 Lipsky @_connectedcare

Dr. John Cush RheumNow ( View Tweet)

Panel Presentation: What’s New in Psoriatic Arthritis. So honored to join my colleagues Alexis Ogdie, Jose Scher, and Jessie Walsh to discuss the latest therapies in PsA https://t.co/Hl5r5xVygK via @YouTube #Rheumnow #ACR2019 #ACR19 #PsA

Links:

Eric Ruderman JointMD ( View Tweet)

Crossreactivity events between allopurinol rashes and febuxostat are very low https://t.co/jVVQhtB0CK

Links:

Dr. John Cush RheumNow ( View Tweet)

New package labeling says febuxostat should only be considered after allopurinol has been tried or is contraindicated. https://t.co/Sk2MhEiOhv

Links:

Dr. John Cush RheumNow ( View Tweet)

PANLAR KOL recommendations for MSUS in gout clinic. Abs #301 https://t.co/uziDzNM0VX #ACR19 @uptoTate @RheumNow

Links:

Dr. John Cush RheumNow ( View Tweet)

Great piece by @jeffsparks and team on the role of airway inflammation and the pathogenesis of RA. #rheumatoidarthritis #rheum https://t.co/E2euIPuRab

Links:

John M. Davis, III JohnDavisIII ( View Tweet)

Abstr# 1161: Gadolinium-enhanced MRI of the shoulders showing inflammatory changes in pts with PMR. Helpful to diagnose and detect recurrence. #ACR19 #ACRBest @RheumNow https://t.co/FMvLYtIr3P
Dr. Paul Sufka psufka ( View Tweet)
Abstract L06 shows the efficacy of Emapalumab, an IFN-γ mAb, when given to 9 systemic JIA pts who developed macrophage activation syndrome. Highly effective showing ability to lower steroid use #ACR19 #ACRBest https://t.co/OXTwpkyhlq
Dr. John Cush RheumNow ( View Tweet)
All the NEW Clinical Practice Guidelines for GOUT! 1. Allopurinol is 1st line 2. Start ULT during flare! 3. No tx for asymptomatic hyperuricemia Seems pretty reasonable - surprised no rec for MTX w/ pegloticase #ACR19 @EBRheum Thank you to @philipcrobinson for posting slides! https://t.co/jWFa8KnWqM
Dr. John Cush RheumNow ( View Tweet)
#ACR19 ABST #1590 -3 RCTs show anti-TNFα & IL-12/23 associated w/significant improvement in depressive symptoms in PSA. GO-REVEAL depression ⬇️ 31.2 to 19.5% w/golimumab; PSUMIT1 36.2 to 20.3% & PSUMIT2 37.2 to 21.2% ⬇️ w/UST. minimal change w/PBO in all 3 trials @DrPetryna

Dr. John Cush RheumNow ( View Tweet)

×